These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 25830038)
1. Review of systemic therapies for locally advanced and metastatic rectal cancer. Yaffee P; Osipov A; Tan C; Tuli R; Hendifar A J Gastrointest Oncol; 2015 Apr; 6(2):185-200. PubMed ID: 25830038 [TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
3. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study. Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382 [TBL] [Abstract][Full Text] [Related]
4. The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review. Benevento I; De Felice F; Musio D; Tombolini V Chemotherapy; 2017; 62(5):314-322. PubMed ID: 28595169 [TBL] [Abstract][Full Text] [Related]
5. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related]
6. Advances in chemotherapy against advanced or metastatic colorectal cancer. Omura K Digestion; 2008; 77 Suppl 1():13-22. PubMed ID: 18204257 [TBL] [Abstract][Full Text] [Related]
7. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157 [TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). Pinto C; Di Bisceglie M; Di Fabio F; Bochicchio A; Latiano T; Cordio S; Rosati G; Aschele C; Marino A; Bergamo F; Bustreo S; Frassineti L; Ciardiello F; Damato A; Giaquinta S; Baldari D; Boni L Oncologist; 2018 Aug; 23(8):912-918. PubMed ID: 29523646 [TBL] [Abstract][Full Text] [Related]
15. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838 [TBL] [Abstract][Full Text] [Related]
16. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749 [TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer. Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797 [TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222 [TBL] [Abstract][Full Text] [Related]
19. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J; Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]